Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $88.67K rose 90.7% year over year, ahead of the +45.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 19.9% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +90.7% holds above the trailing-twelve-month pace of +45.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the cash flow
- Latest · FY2025
- 241.88K USD
- Year-over-year change
- +2.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.88K | +2.8% |
| FY2024 | 2024-12-31 | 235.25K | +100.9% |
| FY2023 | 2023-12-31 | 117.1K | — |
| FY2022 | 2022-12-31 | 200.24K | +79.5% |
| FY2021 | 2021-12-31 | 111.53K | — |
Depreciation & Amortization vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.4% is the highest of 8, against a peer median of -26.6%.
- Over three fiscal years its annual growth of +6.5% compares with a peer median of -9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$40.12M CAD | -6.9% | -23.0% | 12.9% | |
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | $16.25M USD | -28.6% | -9.8% | 6.2% | |
| LTM Mar 2026 | $13.77M USD | -26.6% | -9.0% | 4.5% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $497.04K USD | -32.9% | -29.2% | 2.6% |
| LTM Mar 2026 | $263.19K USD | +45.4% | +6.5% | — | |
| LTM Mar 2026 | $101.93K USD | -1.0% | — | 0.2% | |
| LTM Apr 2026 | CA$5K CAD | -58.3% | -5.9% | — | |
| Peer median (excluding EPRX.TO) | — | -26.6% | -9.8% | 5.4% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (23.37M) | (23.26M) | (28.15M) | (25.74M) | (38.61M) |
| Depreciation & Amortization | 111.53K | 200.24K | 117.1K | 235.25K | 241.88K |
| Deferred Income Tax | 1.2M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.21M | 1.43M | 1.06M | 3.22M | 9.04M |
| Change in Working Capital | (211.43K) | 2.07M | 4.76M | (6.76M) | (726.19K) |
| Accounts Receivables | 190.89K | 310.06K | (105.39K) | (101.39K) | (439K) |
| Inventory | 0 | (1.32M) | (435.12K) | 0 | 0 |
| Accounts Payables | 0 | 1.32M | 435.12K | (714.88K) | 2.4M |
| Other Working Capital | (402.32K) | 1.76M | 4.87M | (5.95M) | (2.69M) |
| Other Non-Cash Items | 3.41M | 776.17K | 1.51M | (944.03K) | 1M |
| Operating Cash Flow | (14.64M) | (18.78M) | (21.02M) | (29.99M) | (29.05M) |
| Capital Expenditures | (431.67K) | (308.37K) | (55.25K) | (104.23K) | (599.26K) |
| Acquisitions (Net) | 0 | 310 | 0 | 39.82K | 0 |
| Purchases of Investments | (9M) | (310) | 0 | 0 | 0 |
| Sales of Investments | 0 | 9.01M | 0 | 0 | 0 |
| Other Investing Activities | (5.02M) | 310 | 0 | 27.81K | 0 |
| Investing Cash Flow | (14.45M) | 8.7M | (73.2K) | (75.16K) | (599.26K) |
| Debt Repayment | 12.17M | (97.49K) | (108.75K) | (9.14M) | 0 |
| Common Stock Issued | 29.67M | 10.64M | 11.96M | 54.56M | 77.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (87.7K) | (87.7K) | 9.11M | 363.06K | 0 |
| Financing Cash Flow | 49.92M | 13.52M | 20.96M | 45.78M | 77.39M |
| Effect of Forex Changes | (81.63K) | 396.83K | 821.4K | (1.96M) | (1.99M) |
| Net Change in Cash | 20.74M | 3.84M | 1.08M | 13.76M | 45.75M |
| Free Cash Flow | (15.07M) | (19.08M) | (21.09M) | (30.1M) | (29.65M) |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.